Article that addresses challenges to enrollment
Posted: Mon Dec 07, 2020 6:18 pm
https://acsjournals.onlinelibrary.wiley ... cncr.31769
Dr. Steensma is a world class premier clinical researcher. Note his recent move to Novartis from the Dana Farber. I have always been curious about his authorship on articles related to Imetelstat while his primary geographical research clinics appeared to be at the Farber which was never a clinical site for any of the Imetelstat studies. In the past I took that to be a negative since the Farber is world class and didn't seem to be too interested in Imetelstat. With Dr. Steensma's interest in MDS and his new position at Novartis one would think that some internal discussion and interest in Imetelstat lies there. The Harvard system can be very hierarchal, take it from me. I hope Dr. Steensma finds himself unfettered and has deep resources as he joins industry. Congratulations and best wishes to a leader in the field. bp
Dr. Steensma is a world class premier clinical researcher. Note his recent move to Novartis from the Dana Farber. I have always been curious about his authorship on articles related to Imetelstat while his primary geographical research clinics appeared to be at the Farber which was never a clinical site for any of the Imetelstat studies. In the past I took that to be a negative since the Farber is world class and didn't seem to be too interested in Imetelstat. With Dr. Steensma's interest in MDS and his new position at Novartis one would think that some internal discussion and interest in Imetelstat lies there. The Harvard system can be very hierarchal, take it from me. I hope Dr. Steensma finds himself unfettered and has deep resources as he joins industry. Congratulations and best wishes to a leader in the field. bp
